Dapoxetine: A new option in the medical management of premature ejaculation

Therapeutic Advances in Urology

Volumn 4, Issue 5, 2012, Pages 233-251

  McMahon, Chris g ^a  

^a Australian Centre for Sexual Health   (Australia)

Author keywords

dapoxetine; premature ejaculation; selective serotonin re uptake inhibitors; treatment

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; DAPOXETINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SERTRALINE; SILDENAFIL; TADALAFIL;

CLINICAL GLOBAL IMPRESSION OF CHANGE; DATA BASE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FATIGUE; HUMAN; INSOMNIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PREMATURE EJACULATION; PREMATURE EJACULATION PROFILE INVENTORY ITEM; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SOMNOLENCE; STOPWATCH MEASURED INTRAVAGINAL EJACULATORY LATENCY TIME; WITHDRAWAL SYNDROME;

EID: 84871872718     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287212453866     Document Type: Review

References (102)

1. Adson D. Kotlyar M. (2003) Premature ejaculation associated with citalopram withdrawal. Ann Pharmacother 37: 1804–1806.
2. Althof S. Abdo C. Dean J. Hackett G. McCabe M. McMahon C. (2010) International Society for Sexual Medicine–s guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 7: 2947–2969.
3. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th ed revised. Washington DC: American Psychiatric Association.
4. Atmaca M. Kuloglu M. Tezcan E. Semercioz A. (2002) The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res 14: 502–505.
5. Black K. Shea C. Dursun S. Kutcher S. (2000) Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 25: 255–261.
6. Buvat J. Tesfaye F. Rothman M. Rivas D. Giuliano F. (2009) Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 55: 957–967.
7. Byers E. Grenier G. (2003) Premature or rapid ejaculation: heterosexual couples– perceptions of men–s ejaculatory behavior. Arch Sex Behav 32: 261–270.
8. Carani C. Isidori A. Granata A. Carosa E. Maggi M. Lenzi A. (2005) Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 90: 6472–6479.
9. Clement P. Bernabe J. Gengo P. Denys P. Laurin M. Alexandre L. (2007) Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine. Eur Urol 51: 825–832.
10. Clement P. Bernabe P. Gengo P. Roussel D. Giuliano F. (2006) Dapoxetine inhibits p-chloroamphetamine-induced ejaculation in anesthetized rats. Book of Abstracts – 8th Congress of the European Society for Sexual Medicine. J Sex Med 55: abstract P-02-159.
11. Coupland N. Bell C. Potokar J. (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16: 356–362.
12. Ditto K. (2003) SSRI discontinuation syndrome. Awareness as an approach to prevention. Postgrad Med 114: 79–84.
13. Dresser M. Desai D. Gidwani S. Seftel A. Modi N. (2006a) Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res 18: 104–110.
14. Dresser M. Kang D. Staehr P. Gidwani S. Guo C. Mulhall J. (2006b) Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal. J Clin Pharmacol 46: 1023–1029.
15. Dresser M. Lindert K. Lin D. (2004) Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clin Pharmacol Ther 75: 113 (abstract P111).
16. Gengo P. Marson L. Gravitt A. (2006) Actions of dapoxetine in ejaculation and sexual behaviour in rats. Book of Abstracts – 8th Congress of the European Society for Sexual Medicine. J Sex Med 28: abstract MP-01-074.
17. Gengo R. Giuliano F. McKenna K. Chester A. Lovenberg T. Bonaventure P. (2005) Monoaminergic transporter binding and inhibition profile of dapoxetine, a medication for the treatment of premature ejaculation. J Urol 173: 230 (abstract 878).
18. Giuliano F. Bernabe J. Gengo P. Alexandre L. Clement P. (2007) Effect of acute dapoxetine administration on the pudendal motoneuron reflex in anesthetized rats: comparison with paroxetine. J Urol 177: 386–389.
19. Giuliano F. Patrick D. Porst H. La Pera G. Kokoszka A. Merchant S. (2008) Premature ejaculation: results from a five-country European observational study. Eur Urol 53: 1048–1057.
20. Godpodinoff M. (1989) Premature ejaculation: clinical subgroups and etiology. J Sex Marital Ther 15: 130–134.
21. Goodman R. (1980) An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res 8(Suppl. 3): 53–59.
22. Hartmann U. Schedlowski M. Kruger T. (2005) Cognitive and partner-related factors in rapid ejaculation: differences between dysfunctional and functional men. World J Urol 10: 10.
23. Hatzimouratidis K. Amar E. Eardley I. Giuliano F. Hatzichristou D. Montorsi F. (2010) Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 57: 804–814.
24. Hellstrom W. Althof S. Gittelman M. Streidle C. Ho K. Kell S. (2005) Dapoxetine for the treatment of men with premature ejaculation (PE):dose-finding analysis. J Urol 173: 238 (abstract 877).
25. Hellstrom W. Gittelman M. Althof S. (2004) Dapoxetine HCl for the treatment of premature ejaculation: a phase II, randomised, double-blind, placebo controlled study. J Sex Med 1(Suppl. 1): 59 (abstract 097).
26. Hyun J. Kam S. Kwon O. (2008) Changes of cerebral current source by audiovisual erotic stimuli in premature ejaculation patients. J Sex Med 5: 1474–1481.
27. Jannini E. Lenzi A. (2005) Epidemiology of premature ejaculation. Curr Opin Urol 15: 399–403.
28. Jannini E. Maggi M. Lenzi A. (2011) Evaluation of premature ejaculation. J Sex Med 8(Suppl. 4): 328–334.
29. Jannini E. Simonelli C. Lenzi A. (2002) Sexological approach to ejaculatory dysfunction. Int J Androl 25: 317–323.
30. Janssen P. Bakker S. Rethelyi J. Zwinderman A. Touw D. Olivier B. (2009) Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J Sex Med 6: 276–284.
31. Jeong I. Kim S. Yoon S. Hahn S. (2012) Block of cloned Kv4.3 potassium channels by dapoxetine. Neuropharmacology 62: 2261–2266.
32. Jern P. Santtila P. Witting K. Alanko K. Harlaar N. Johansson A. (2007) Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of Finnish twins. J Sex Med 4: 1739–1749.
33. Kara H. Aydin S. Yucel M. Agargun M. Odabas O. Yilmaz Y. (1996) The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol 156: 1631–1632.
34. Kaufman J. Rosen R. Mudumbi R. Tesfaye F. Hashmonay R. Rivas D. (2009) Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int 103: 651–658.
35. Khan A. Khan S. Kolts R. Brown W. (2003) Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 160: 790–792.
36. Kowey P. Mudumbi R. Aquilina J. Dibattiste P. (2011) Cardiovascular safety profile of dapoxetine during the premarketing evaluation. Drugs R D 11: 1–11.
37. Lane R. (1997) A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol 11: 72–82.
38. Laumann E. Nicolosi A. Glasser D. Paik A. Gingell C. Moreira E. (2005) Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 17: 39–57.
39. Laumann E. Paik A. Rosen R. (1999) Sexual dysfunction in the United States: prevalence and predictors. JAMA 281: 537–544.
40. Livni E. Satterlee W. Robey R. Alt C. Van Meter E. Babich J. (1994) Synthesis of [11C]dapoxetine.HCl, a serotonin re-uptake inhibitor: biodistribution in rat and preliminary PET imaging in the monkey. Nucl Med Biol 21: 669–675.
41. Mann J. Emslie G. Baldessarini R. Beardslee W. Fawcett J. Goodwin F. (2006) ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 31: 473–492.
42. Masters W. Johnson V. (1970) Human Sexual Inadequacy. Boston, MA: Little Brown, pp. 92–115.
43. McMahon C. (1998) Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 159: 1935–1938.
44. McMahon C. (2002) Long term results of treatment of premature ejaculation with selective serotonin re-uptake inhibitors. Int J Impot Res 14(Suppl. 3): S19.
45. McMahon C. (2008) Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies – part II – study design, outcome measures, data analysis, and reporting. J Sex Med 5: 1817–1833.
46. McMahon C. Abdo C. Incrocci L. Perelman M. Rowland D. Waldinger M. (2004) Disorders of orgasm and ejaculation in men. J Sex Med 1: 58–65.
47. McMahon C. Althof S. Kaufman J. Buvat J. Levine S. Aquilina J. (2011) Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med 8: 524–539.
48. McMahon C. Althof S. Waldinger M. Porst H. Dean J. Sharlip I. (2008) An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med 5: 1590–1606.
49. McMahon C. Kim S. Park N. Chang C. Rivas D. Tesfaye F. (2010) Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 7: 256–268.
50. McMahon C. Porst H. (2011) Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation. J Sex Med 8: 2707–2725.
51. Metz M. McCarthy B. (2003) Coping with Premature Ejaculation: How to Overcome PE, Please your Partner and Have Great Sex. Oakland, CA: New Harbinger Publications.
52. Metz M. Pryor J. (2000) Premature ejaculation: a psychophysiological approach for assessment and management. J Sex Marital Ther 26: 293–320.
53. Metz M. Pryor J. Nesvacil L. Abuzzahab F. Sr Koznar J. (1997) Premature ejaculation: a psychophysiological review. J Sex Marital Ther 23: 3–23.
54. Modi N. Dresser M. Desai D. Edgar C. Wesnes K. (2007) Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol 47: 315–322.
55. Modi N. Dresser M. Simon M. Lin D. Desai D. Gupta S. (2006) Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 46: 301–309.
56. Modi N. Kell S. Aquilina J. Rivas D. (2008) Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin. J Clin Pharmacol 48: 1438–1450.
57. Modi N. Nath R. Staehr P. Gupta S. Aquilina J. Rivas D. (2009) Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. J Clin Pharmacol 49: 634–642.
58. Montague D. Jarow J. Broderick G. Dmochowski R. Heaton J. Lue T. (2004) AUA guideline on the pharmacologic management of premature ejaculation. J Urol 172: 290–294.
59. Montejo A. Llorca G. Izquierdo J. Rico-Villademoros F. (2001) Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 62(Suppl. 3): 10–21.
60. Montorsi F. (2005) Prevalence of premature ejaculation: a global and regional perspective. J Sex Med 2(Suppl. 2): 96–102.
61. Ng G. (2006) Treating patients with ventricular ectopic beats. Heart 92: 1707–1712.
62. Nicolosi A. Laumann E. Glaser D. Moreira E. Paik A. Gingell C. (2004) Global study of sexual attitudes and behaviors investigator–s group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 64: 991–997.
63. Olivier B. van Oorschot R. Waldinger M. (1998) Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol 13(Suppl. 6): S9–S14.
64. Pastore A. Palleschi G. Leto A. Pacini L. Iori F. Leonardo C. (2012) A prospective randomized study to compare pelvic floor rehabilitation and dapoxetine for treatment of lifelong premature ejaculation. Int J Androl 9 February (epub ahead of print).
65. Patrick D. Althof S. Pryor J. Rosen R. Rowland D. Ho K. (2005) Premature ejaculation: an observational study of men and their partners. J Sex Med 2: 358–367.
66. Patrick D. Giuliano F. Ho K. Gagnon D. McNulty P. Rothman M. (2009) The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice. BJU Int 103: 358–364.
67. Pattij T. Olivier B. Waldinger M. (2005) Animal models of ejaculatory behavior. Curr Pharm Des 11: 4069–4077.
68. Peugh J. Belenko S. (2001) Alcohol, drugs and sexual function: a review. J Psychoactive Drugs 33: 223–232.
69. Porst H. McMahon C. Althof S. Sharlip I. Bull S. Aquilina J. (2010) Baseline characteristics and treatment outcome for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of three phase 3 dapoxetine trials. J Sex Med 7: 2231–2242.
70. Porst H. Montorsi F. Rosen R. Gaynor L. Grupe S. Alexander J. (2007) The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 51: 816–823.
71. Pryor J. Althof S. Steidle C. Rosen R. Hellstrom W. Shabsigh R. (2006) Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 368: 929–937.
72. Radley D. Finkelstein S. Stafford R. (2006) Off-label prescribing among office-based physicians. Arch Intern Med 166: 1021–1026.
73. Rowland D. McMahon C. Abdo C. Chen J. Jannini E. Waldinger M. (2010) Disorders of orgasm and ejaculation in men. J Sex Med 7: 1668–1686.
74. Salonia A. Rocchini L. Sacca A. Pellucchi F. Ferrari M. Carro U. (2009) Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Sex Med 6: 2868–2877.
75. Schapiro B. (1943) Premature ejaculation, a review of 1130 cases. J Urol 50: 374–379.
76. Screponi E. Carosa E. Di Stasi S. Pepe M. Carruba G. Jannini E. (2001) Prevalence of chronic prostatitis in men with premature ejaculation. Urology 58: 198–202.
77. Segraves R. (2010) Considerations for an evidence-based definition of premature ejaculation in the DSM-V. J Sex Med 7: 672–679.
78. Semans J. (1956) Premature ejaculation: a new approach. South Med J 49: 353–358.
79. Serefoglu E. Cimen H. Atmaca A. Balbay M. (2009) The distribution of patients who seek treatment for the complaint of ejaculating prematurely according to the four premature ejaculation syndromes. J Sex Med 7: 810–815.
80. Serefoglu E. Yaman O. Cayan S. Asci R. Orhan I. Usta M. (2011) The comparison of premature ejaculation assessment questionnaires and their sensitivity for the four premature ejaculation syndromes: results from the Turkish society of andrology sexual health survey. J Sex Med 8: 1177–1185.
81. Shabsigh R. Patrick D. Rowland D. Bull S. Tesfaye F. Rothman M. (2008) Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine. BJU Int 102: 824–828.
82. Sorbera L. Castaner J. Castaner R. (2004) Dapoxetine hydrochloride. Drugs Future 29: 1201–1205.
83. Symonds T. Roblin D. Hart K. Althof S. (2003) How does premature ejaculation impact a man–s life? J Sex Marital Ther 29: 361–370.
84. Tamam L. Ozpoyraz N. (2002) Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv Ther 19: 17–26.
85. Thyssen A. Sharma O. Tianmei S. Aquilina J. Vandebosch A. Wang S. (2010) Pharmacokinetics of dapoxetine hydrochloride in healthy Chinese, Japanese, and Caucasian men. J Clin Pharmacol 50: 1450–1460.
86. Waldinger M. (2003) Towards evidenced based drug treatment research on premature ejaculation: a critical evaluation of methodology. J Impot Res 15: 309–313.
87. Waldinger M. (2006) The need for a revival of psychoanalytic investigations into premature ejaculation. J Mens Health & Gender 3: 390–396.
88. Waldinger M. (2007) Premature ejaculation: definition and drug treatment. Drugs 67: 547–568.
89. Waldinger M. Berendsen H. Blok B. Olivier B. Holstege G. (1998b) Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 92: 111–118.
90. Waldinger M. Hengeveld M. Zwinderman A. Olivier B. (1998a) An empirical operationalization of DSM-IV diagnostic criteria for premature ejaculation. Int J Psychiatry Clin Pract 2: 287–293.
91. Waldinger M. Hengeveld M. Zwinderman A. (1994) Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 151: 1377–1379.
92. Waldinger M. Quinn P. Dilleen M. Mundayat R. Schweitzer D. Boolell M. (2005a) A multinational population survey of intravaginal ejaculation latency time. J Sex Med 2: 492–497.
93. Waldinger M. Rietschel M. Nothen M. Hengeveld M. Olivier B. (1998c) Familial occurrence of primary premature ejaculation. Psychiatr Genet 8: 37–40.
94. Waldinger M. Schweitzer D. (2006) Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II – proposals for DSM-V and ICD-11. J Sex Med 3: 693–705.
95. Waldinger M. Schweitzer D. (2008) The use of old and recent DSM definitions of premature ejaculation in observational studies: a contribution to the present debate for a new classification of PE in the DSM-V. J Sex Med 5: 1079–1087.
96. Waldinger M. Zwinderman A. Olivier B. Schweitzer D. (2005b) Proposal for a definition of lifelong premature ejaculation based on epidemiological stopwatch data. J Sex Med 2: 498–507.
97. Waldinger M. Zwinderman A. Olivier B. Schweitzer D. (2007) The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med 4: 1028–1037.
98. Waldinger M. Zwinderman A. Olivier B. Schweitzer D. (2008) Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy. J Sex Med 5: 492–499.
99. Waldinger M. Zwinderman A. Schweitzer D. Olivier B. (2004) Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 16: 369–381.
100. World Health Organization (1994) International Classification of Diseases and Related Health Problems (10th ed.). Geneva: World Health Organization.
101. Zajecka J. Fawcett J. Schaff M. Jeffriess H. Guy C. (1991) The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 52: 66–68.
102. Zajecka J. Tracy K. Mitchell S. (1997) Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 58: 291–297.